This article was originally published in The Gray Sheet
Extends to Nov. 10 the expiration of its offer to purchase for cash any and all of the $100 mil. aggregate principal amount of its outstanding 10-1/2% senior subordinated notes due 2006. Holders of over $99.9 mil. of the notes had tendered their notes and delivered consents to amendments prior to the consent expiration date. Previously scheduled to expire on Oct. 29, the tender offer was launched in connection with Maxxim's previously announced proposal to merge with Fox Paine Medic Acquisition Corporation and recapitalize the company (1"The Gray Sheet" June 21, p. 19). The merger is expected to close in "mid-November," Maxxim says
You may also be interested in...
The management of Maxxim Medical plans to take the specialty medical products company private with the help of Foster City, California-based investment firm Fox Paine & Company and Chase Manhattan.
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.